X4 Pharmaceuticals begins Phase II trial of X4P-001 to treat ccRCC
US-based biotechnology firm X4 Pharmaceuticals has begun the Phase II portion of its ongoing Phase I/II clinical trial with dosing of X4P-001 in combination with Inlyta (axitinib) in advanced clear cell renal cell carcinoma (ccRCC) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Renal Cell Carcinoma